Autoimmune Diseases / 2012 / Article / Tab 1

Clinical Study

Improved Metabolic Control in Diabetes, HSP60, and Proinflammatory Mediators

Table 1

Characteristics of patients enrolled in the study.

PatientAgeSexBMIHgbA1C (n.v. 6,6)HOMAWaist circum (cm)Diabetes treatment: drugs (+diet and physical activity)Lenght of treatment (years/months) Comorbidties
BeforeAfterBeforeAfterBeforeAfterBeforeAfter

151M35348.57.22.93.6136112Gliclazid0/3HTN, DL
266M303015.66.06.06.0104100Repaglinid0/6HTN, DL
352F31317.96.37.36.99889Metformin0/6HTN, DL
467F36357.36.75.05.2113105Metformin1/2HTN, DL, CVA
564M28247.35.61.30.910493Metformin0/6HTN, DL
665F27.525.59.56.75.11.9113104Metformin1/0HTN, DL
767M31277.95.84.82.310796Metformin0/5HTN, DL
860M31309.47.25.63.910396Metformin0/2HTN, DL
974F37337.76.63.21.8124107Metformin + Repaglinid1/2HTN, DL, Afib
1067F38348.46.48.72.5136128Metformin + Glimepirid0/6HTN, DL
1150M292712.06.93.81.696106Metformin + Glimepirid0/6HTN, DL
1271F40388.46.55.63.9133127Metformin0/8HTN, DL
1371F43398.26.75.72.6109109Metformin0/5HTN, DL
1473F322986.94.53.8102102Metformin0/8HTN, DL
1559F41409.16.710.94.0121118Metformin1/5HTN, DL
1655F41398.46.96.02.3123102Metformin0/2HTN, DL
1747M31298.86.69.53.510496Metformin1/9HTN, DL

Pat: patient; n.v: normal value; circum: circumference; treatment: Treatment; comorbidities: cardiovascular comorbidities; HTN: hypertension; DL: dyslipidemia; CVA: cerebral vascular accident; Afib: atrial fibrillation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.